NCT07043634View on ClinicalTrials.gov

A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects

PHASE3RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 15, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Bioavailability Heathy Volunteers
Interventions
COMBINATION_PRODUCT

FDC (24 mg ER torsemide and 30 mg Spironolactone) without food

FDC without food

COMBINATION_PRODUCT

FDC (24 mg ER torsemide and 30 mg Spironolactone) with food

FDC with food

Trial Locations (1)

22182

RECRUITING

Sarfez Pharmaceuticals, Vienna

All Listed Sponsors
lead

Sarfez Pharmaceuticals, Inc.

INDUSTRY